Clinical Trials on Idiopathic Immune Complex-Mediated Glomerulonephritis in Argentina

Total 70 results

Apellis Pharmaceuticals, Inc.

Active, not recruiting

Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN (NOBLE)

Renal Transplant | C3G | IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Complement 3 Glomerulopathy | Complement 3 Glomerulopathy (C3G) | Complement 3 Glomerulonephritis | Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis (MPGN) | Immune Complex Membranoproliferative... and other conditions

United States, Australia, Austria, United Kingdom, Brazil, Argentina, France, Italy, Netherlands, Spain, Switzerland
Apellis Pharmaceuticals, Inc.

Active, not recruiting

Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis (VALIANT)

C3G | IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Complement 3 Glomerulopathy | Complement 3 Glomerulopathy (C3G) | Complement 3 Glomerulonephritis | Dense Deposit Disease | DDD | Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis (MPGN) | Immune Complex Membranoproliferative...

United States, Spain, France, Germany, United Kingdom, Netherlands, Brazil, Israel, Japan, Australia, Austria, Italy, Switzerland, Korea, Republic of, Czechia, Belgium, Argentina, Canada, Poland
Hospital Britanico

Completed

Inhibition of the Renin Angiotensin System Plus Corticosteroids for the Treatment of Proteinuria in IGA Nephropathy

IGA Nephropathy

Argentina
argenx

Recruiting

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy (ALKIVIA+)

Myositis | Dermatomyositis | Polymyositis | Antisynthetase Syndrome | Immune-Mediated Necrotizing Myopathy | Active Idiopathic Inflammatory Myopathy

Korea, Republic of, Thailand, United States, Bulgaria, Taiwan, Argentina, Belgium, Cyprus, Denmark, France, Georgia, Germany, Greece, Italy, Lithuania, Czechia, Sweden
argenx

Recruiting

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. (ALKIVIA)

Myositis | Dermatomyositis | Polymyositis | Antisynthetase Syndrome | Immune-Mediated Necrotizing Myopathy | Active Idiopathic Inflammatory Myopathy

United States, Germany, Spain, Korea, Republic of, Austria, Turkey, Lithuania, Australia, Thailand, Serbia, Poland, Italy, France, Netherlands, Argentina, United Kingdom, Georgia, Belgium, Bulgaria, Canada, Cyprus, Denmark, Greece, Hu... and more
Liga Panamericana de Asociaciones de Reumatologia...
Janssen Research & Development, LLC

Recruiting

Serological and Urinary Biomarkers in Latin American Patients With Systemic Lupus Erythematosus: GLADEL 2.0 Cohort

Lupus Nephritis

Argentina
Hospital de Clinicas José de San Martín

Unknown

Lupus Flares and Histological Renal Activity at the End of the Treatment (LuFla) (LuFla)

Lupus Nephritis

Argentina
Novartis Pharmaceuticals

Terminated

Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy

Glomerulonephritis, Membranous

Czechia, India, Taiwan, United Kingdom, Germany, Argentina, China, Netherlands, Spain
Mallinckrodt ARD LLC

Completed

Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria (PODOCYTE)

Idiopathic Focal Segmental Glomerulosclerosis

United States, Argentina, Turkey, Peru, Australia, Chile, Mexico
Novartis Pharmaceuticals

Completed

Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation

IgA Nephropathy

Colombia, Taiwan, Czechia, India, Turkey, Belgium, Netherlands, Singapore, Australia, Korea, Republic of, Thailand, Argentina, Germany, Israel, Japan, Sweden, United Kingdom, Brazil, China, Hong Kong, Norway, Finland, France, Denmark, M...
Hoffmann-La Roche

Completed

A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)

Juvenile Idiopathic Arthritis

Belgium, Canada, United States, Argentina, Poland, Spain, Germany, Hungary
Sanofi
Regeneron Pharmaceuticals

Recruiting

A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)

Juvenile Idiopathic Arthritis

Argentina, Bulgaria, Canada, Finland, France, Germany, Ireland, Italy, Russian Federation, Spain, United Kingdom
Chinook Therapeutics, Inc.

Recruiting

A Study of BION-1301 in Adults With IgA Nephropathy

Immunoglobulin A Nephropathy | IgA Nephropathy

United States, Canada, Australia, Argentina, Korea, Republic of
Novartis Pharmaceuticals

Recruiting

Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN (APPARENT)

IC-MPGN

France, Germany, Spain, Switzerland, Japan, United States, Canada, India, United Kingdom, Israel, Brazil, Turkey, Italy, Vietnam, Argentina, Czechia, Poland
Hoffmann-La Roche

Active, not recruiting

A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy (MAJESTY)

Primary Membranous Nephropathy

United States, China, Spain, Argentina, Brazil, France, Italy, Russian Federation, Israel, Poland, Turkey, Ukraine
Bio Products Laboratory

Completed

A Study to Find How Safe and Effective GAMMAPLEX® is in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Chronic Idiopathic Thrombocytopenic Purpura

United States, India, Argentina
Novartis Pharmaceuticals
Pediatric Rheumatology International Trials Organization

Completed

Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) (β-SPECIFIC 2)

Systemic Juvenile Idiopathic Arthritis With Active Flare

United States, Argentina, Canada, Switzerland, Germany, Israel, South Africa, Belgium, Italy, Spain, France, Brazil, Turkey, Hungary, Poland, Norway, Sweden, Netherlands, Peru
UCB BIOSCIENCES GmbH
PRA Health Sciences

Completed

Pediatric Arthritis Study of Certolizumab Pegol (PASCAL)

Polyarticular-course Juvenile Idiopathic Arthritis (JIA)

United States, Argentina, Brazil, Canada, Chile, Mexico, Russian Federation
Hoffmann-La Roche

Completed

A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis

Juvenile Idiopathic Arthritis

United States, Canada, United Kingdom, Brazil, Argentina, Germany, Italy, Russian Federation, Spain, Mexico, Australia, France
Novartis Pharmaceuticals

Recruiting

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

Primary IgA Nephropathy

Japan, Korea, Republic of, United States, Denmark, France, Taiwan, Belgium, Israel, Thailand, Germany, India, Czechia, Malaysia, Argentina, Singapore, China, Australia, Norway, Turkey, United Kingdom, Brazil, Hong Kong, Netherlands, C... and more
Hoffmann-La Roche

Completed

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)

Juvenile Idiopathic Arthritis

Belgium, Italy, Spain, United States, Greece, Germany, Australia, Brazil, Argentina, Canada, United Kingdom, Poland, Denmark, Norway, Mexico, Slovakia, Sweden, Czech Republic, Netherlands
Chinook Therapeutics U.S., Inc.

Active, not recruiting

Atrasentan in Patients With IgA Nephropathy (ALIGN)

Immunoglobulin A Nephropathy | IgA Nephropathy

United States, Spain, Taiwan, Hong Kong, China, New Zealand, United Kingdom, Korea, Republic of, Canada, Australia, Germany, France, India, Japan, Argentina, Italy, Brazil, Colombia, Poland, Portugal
Bristol-Myers Squibb

Completed

Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)

Active Polyarticular Juvenile Idiopathic Arthritis

United States, Spain, Belgium, Italy, Argentina, Brazil, France, Germany, Mexico, Peru, Russian Federation, South Africa
Omeros Corporation

Terminated

Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy

IgA Nephropathy

United States, Argentina, Australia, Belgium, Bulgaria, Canada, Czechia, Germany, Greece, Hungary, India, Italy, Korea, Republic of, Lithuania, Poland, Singapore, Slovakia, Spain, Sweden, Taiwan, Thailand, Turkey, United Kingdom
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients (APPLAUSE-IgAN)

IgA Nephropathy

United States, Taiwan, Czechia, Germany, Hungary, India, Turkey, Belgium, Netherlands, Singapore, Australia, Canada, Italy, Korea, Republic of, Spain, Thailand, Denmark, Slovenia, United Kingdom, Argentina, Brazil, Israel, Japan, France, Swed... and more
Calliditas Therapeutics AB

Completed

Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy (Nefigard)

Primary IgA Nephropathy

United States, Australia, Taiwan, Spain, Canada, Argentina, Belarus, Belgium, Czechia, Finland, France, Germany, Greece, Italy, Korea, Republic of, Poland, Sweden, Turkey, United Kingdom
Novartis Pharmaceuticals
International Maternal Pediatric Adolescent AIDS Clinical Trials Group; Southwest...

Terminated

Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA) (β-SPECIFIC 1)

Systemic Juvenile Idiopathic Arthritis

United States, Argentina, Canada, Switzerland, Germany, United Kingdom, Israel, South Africa, Belgium, Greece, Italy, Spain, France, Brazil, Turkey, Hungary, Poland, Norway, Sweden, Netherlands, Peru, Denmark
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Efficacy and Safety of RO7434656 in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression (IMAGINATION)

Primary IgA Nephropathy

Korea, Republic of, Australia, Spain, United Kingdom, Taiwan, China, Japan, France, United States, Italy, Greece, Czechia, Singapore, Hong Kong, Argentina, Malaysia, Germany, Brazil, Poland, Canada
Alexion Pharmaceuticals, Inc.

Recruiting

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) (ICAN)

Immunoglobulin A Nephropathy | IgAN

Spain, United Kingdom, United States, Italy, Korea, Republic of, Belgium, Germany, Colombia, Japan, China, France, Saudi Arabia, Thailand, Australia, Canada, Brazil, Malaysia, Poland, Taiwan, Austria, Greece, Israel, Netherlands, Arge... and more
HI-Bio

Recruiting

A Study of Felzartamab in Participants With Lupus Nephritis

Lupus Nephritis

United States, Argentina, Australia, Canada
Novartis Pharmaceuticals
Pediatric Rheumatology International Trials Organization

Completed

An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever. (β-SPECIFIC 3)

Systemic Juvenile Idiopathic Arthritis

Italy, United States, Belgium, Germany, Greece, Russian Federation, Turkey, Spain, France, Israel, Canada, Hungary, Switzerland, United Kingdom, Brazil, Austria, Sweden, Netherlands, Argentina, Peru, Poland
Alexion Pharmaceuticals, Inc.

Recruiting

Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

Lupus Nephritis | Immunoglobulin A Nephropathy | IgAN | LN

Australia, Spain, United Kingdom, China, Germany, Italy, Argentina, Peru, Korea, Republic of, Taiwan, Thailand, United States, Serbia, Israel, Brazil, Turkey, Mexico, Russian Federation
Sanofi
Regeneron Pharmaceuticals

Completed

An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) (SKYPP)

Juvenile Idiopathic Arthritis

United States, Argentina, Canada, Chile, Czechia, Finland, France, Germany, Italy, Mexico, Netherlands, Poland, Russian Federation, Spain, United Kingdom
Hoffmann-La Roche

Completed

A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)

Juvenile Idiopathic Arthritis

Canada, Mexico, United States, Argentina, Germany, Israel, Italy, Russian Federation, Spain, United Kingdom
Biogen

Terminated

BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis

Lupus Nephritis

Belgium, Peru, Italy, Malaysia, Australia, Argentina, United States, Hong Kong, Hungary, Poland, Colombia, Russian Federation, Philippines, Brazil, France, Korea, Republic of, Mexico, Spain, Thailand
Eli Lilly and Company

Recruiting

A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)

Systemic Juvenile Idiopathic Arthritis

Belgium, Spain, India, Italy, Czechia, Japan, Austria, France, United Kingdom, Brazil, Mexico, Israel, Poland, Argentina, Denmark, Turkey
Faes Farma, S.A.

Completed

Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria

Urticaria

Argentina, Belgium, France, Germany, Poland, Romania, Spain
Pfizer

Completed

A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA

Arthritis Juvenile Idiopathic

United States, Belgium, Spain, Canada, Mexico, Turkey, Israel, China, Slovakia, Hungary, India, Argentina, Brazil, Germany, South Africa, Poland, Ukraine, Italy, Costa Rica, Russian Federation, United Kingdom
Hoffmann-La Roche

Completed

A Study of Subcutaneously (SC) Administered Tocilizumab (TCZ) in Participants With Polyarticular-Course Juvenile Idiopathic Arthritis (pJIA) (JIGSAW 117)

Juvenile Idiopathic Arthritis

Spain, Mexico, Germany, United States, Russian Federation, Australia, Italy, Argentina, Brazil, Canada, France, United Kingdom
Hoffmann-La Roche

Completed

Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis

Juvenile Idiopathic Arthritis

United States, Canada, United Kingdom, Brazil, Germany, Italy, Russian Federation, Spain, Australia, France, Mexico, Argentina
Biogen

Terminated

BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis (ATLAS)

Lupus Nephritis

United States, Peru, Belgium, Italy, Philippines, Malaysia, Hong Kong, Argentina, Germany, Hungary, Australia, Colombia, Russian Federation, Portugal, Mexico, Korea, Republic of, France, Thailand, Brazil, Poland, Spain
AstraZeneca
Parexel

Completed

Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis (TULIP-LN1)

Lupus Nephritis

United States, Italy, Spain, Taiwan, Peru, Belgium, France, Korea, Republic of, Mexico, Germany, Australia, Hungary, Serbia, Russian Federation, United Kingdom, Poland, Argentina
Novartis Pharmaceuticals

Completed

Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis.

Lupus Nephritis

China, Taiwan, Hungary, Korea, Republic of, Germany, Turkey, Argentina, Russian Federation, Hong Kong, Tunisia
Hoffmann-La Roche
Aspreva Pharmaceuticals

Completed

A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.

Lupus Nephritis

Belgium, Germany, Italy, Spain, Canada, France, Portugal, United States, Greece, Mexico, United Kingdom, Australia, China, Hungary, Argentina, Brazil, Czech Republic
Hoffmann-La Roche

Completed

A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis

Juvenile Idiopathic Arthritis

Belgium, Canada, United States, United Kingdom, Argentina, Germany, Italy, Russian Federation, Spain, Mexico, Poland, Brazil, Australia, France, Peru
GlaxoSmithKline

Completed

Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body. (PETIT2)

Idiopathic Thrombocytopenic Purpura

Thailand, Israel, Poland, Russian Federation, Spain, Germany, United Kingdom, Taiwan, Hong Kong, Czech Republic, Italy, United States, Argentina
Pfizer

Completed

Efficacy Study Of Tofacitinib In Pediatric JIA Population

Juvenile Idiopathic Arthritis

United States, Spain, Turkey, Canada, Australia, Israel, United Kingdom, Argentina, Brazil, Poland, Mexico, Belgium, Russian Federation, Ukraine
Human Genome Sciences Inc., a GSK Company
GlaxoSmithKline

Completed

Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis (BLISS-LN)

Lupus Nephritis

United States, Korea, Republic of, Spain, Mexico, Philippines, Thailand, France, Germany, Belgium, Hong Kong, Taiwan, Canada, China, Argentina, United Kingdom, Brazil, Colombia, Czechia, Hungary, Netherlands, Russian Federation
Novartis Pharmaceuticals

Recruiting

A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies

Primary Immune Thrombocytopenia (ITP)

Spain, Italy, France, Germany, China, Korea, Republic of, Czechia, Turkey, Malaysia, United States, Argentina, Australia, United Kingdom, Poland
Bristol-Myers Squibb

Terminated

Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis

Lupus Nephritis

Australia, China, Italy, Taiwan, Turkey, United States, Hong Kong, Spain, Russian Federation, Korea, Republic of, Japan, Israel, Romania, Puerto Rico, Argentina, Brazil, Canada, Chile, Colombia, Czechia, India, Mexico, Peru

Clinical Trials on Idiopathic Immune Complex-Mediated Glomerulonephritis in Argentina

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations